Intestinal Disorders News

As any self-respecting American marijuana smoker can attest, the nation’s complicated relationship with the drug dates at least as far back as the Founding Fathers: Both George Washington and Thomas Jefferson were known to grow acres of hemp — marijuana’s far less-psychoactive cannabis cousin — on their Virginia plantations.

SAN DIEGO — Eosinophil counts in the colon are associated with current but not incident depression, according to study results presented at Digestive Disease Week.

SAN DIEGO — Over the next four days, the gastroenterology community will convene in the San Diego Convention Center for Digestive Disease Week 2019, the specialty’s largest scientific conference.

The United States FDA has approved an extension of the indication for Gattex to include injection in pediatric patients with short bowel syndrome aged 1 year and older who need additional nutrition fluids through intravenous feeding, according to company press release.

Women with obesity are at increased risk for developing diverticulosis while hormones seem to be at play as well, according to research published in Clinical Gastroenterology and Hepatology.

Surgical intervention for a patient’s first occurrence of adhesive small bowel obstruction significantly reduced the risk for recurrence, according to results of a longitudinal, retrospective cohort study. This finding challenges the current standard of care, in which surgical intervention was thought to raise the risk for recurrence.

The American Gastroenterological Association has named the 2019 winners of its annual Recognition Awards, bestowed on leaders in gastroenterology to honor their contribution and achievements in the specialty.

The European Commission has granted an orphan drug designation to Therachon’s apraglutide for the treatment of short bowel syndrome, according to a company press release.

ArTara Therapeutics has completed an end-of-phase 2 meeting with the FDA to discuss a phase 3 study of intravenous choline chloride substrate replacement for patients with intestinal failure-associated liver disease, according to a press release.

The FDA has accepted the filing of a new drug application to extend the use of Gattex for injection in children aged 1 to 17 years with short bowel syndrome, according to a company press release.